Tirzepatide/Cagrilinitide Pen – 20/4 mg
Tirzepatide/Cagrilinitide Pen – 20/4 mg
Advanced triple-hormone pathway formula combining dual incretin agonism (GLP-1/GIP) with amylin receptor activation to deliver enhanced appetite suppression, prolonged satiety, and superior metabolic support for weight management.
Tirzepatide acts as a dual GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide) receptor agonist, improving insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Cagrilinitide, a long-acting amylin (and calcitonin receptor) analog, further enhances satiety signals via the brainstem, slows gastric emptying, and complements incretin effects for greater overall reduction in food intake and body weight. This synergistic combination targets multiple complementary pathways involved in energy homeostasis.
Strength: 8.33 mg/mL (20 mg cartridge) Tirzepatide + 1.67 mg/mL (4 mg cartridge) Cagrilinitide
Volume: 2.4 mL
Dosage Form: Subcutaneous injection (disposable)
Medical Requirement: Baseline blood tests are necessary prior to prescribing. Simply share your recent results with us or request a blood test from our CeleRevive doctor.
Note: All products available through the CeleRevive platform are of high purity and are sourced from GMP-compliant manufacturing facilities. All injectables are >98-99% purity. Products are imported and distributed by fully licensed wholesale pharmacies, compounded and dispensed by fully licensed, compliant compounding pharmacies, and supplied only upon prescription by our licensed medical practitioner.
Regulatory Status: Tirzepatide is a Registered and Established Medicine, while Cagrilinitide is classified as an Investigational / Experimental Product in South Africa. This combination is supplied on a patient-specific basis via prescription from a licensed medical practitioner through licensed compounding pharmacies as an experimental or off-label product. Note that compounded versions of these products for weight management are subject to strict regulatory oversight.